Latest News: 25 Million Dollar Wrongful Death Truck Verdict

BLOG TAG: Paxil

News & Commentary

Yale Paxil Study Alleged Promotional Scheme

Yale Paxil Study Alleged Promotional Scheme

A Yale Daily News article explains that a “School of Medicine faculty member has been accused of signing her name to a ghostwritten study” for a report on the antidepressant, Paxil. According to the news article, this is “a practice that many believe amounts to plagiarism and undermines scientific integrity.”

The Yale Daily News goes on to explain that “The nonprofit watchdog Project on Government Oversight (POGO) claims that School of Medicine associate professor Kimberly Yonkers signed her name to work that was not her own in a 2003 report.”  POGO contacted the National Institutes of Health, which funds some of Yonkers’ research, “identifying about four separate cases of alleged ghostwriting,” the Daily News alleges.

According to the article, “One of these was Yonkers’ study, which POGO claims was part of a promotion scheme by pharmaceutical company GlaxoSmithKline to increase Paxil sales.” The Yale newspaper explains that Yonkers denied these accusations, saying she was “extensively involved in writing and editing the report.”

Yale reports that Robert Alpern, the School of Medicine Dean, was unaware of this report until recently contacted for interview. According to the Daily News, Alpern said “‘We will examine the situation thoroughly before we make a decision to investigate.’”

However, this latest story from Yale adds to other allegations of dishonesty regarding the marketing of Paxil. A recent Bloomberg article alleges that GlaxoSmithKline, the manufacturer of Paxil, failed to report the risk of birth defect to children of mothers taking the drug.

The article further explains that Glaxo has been involved in numerous legal problems regarding their products, including a trial that ended in July with the company agreeing “to pay more than $1 billion to settle 800 cases alleging the company failed to adequately warn consumers and their doctors about the drug’s hazards.”

According to Bloomberg, in total Glaxo “has paid more than $2 billion to resolve litigation over Paxil, including claims the anti-depressant caused suicides in some users and withdrawal symptoms.” According to a lawyer for one of the victims of this product, “Glaxo had research from the 1980s showing Paxil caused deaths among the offspring of animal test subjects and didn’t provide clear warnings about the deaths,” Bloomberg reports.

These allegations regarding the study of Paxil threaten to hurt the company further as it attempts to restore its image and goes to trial. However, these recent allegations might further hurt the company as it attempts to rebound.

To address the ghostwritten study, The Yale Daily News reports that according to Alpern, “the Provost has incorporated the Yale Medical Group’s updated authorship guidelines into the Universitywide policy. Both University and Yale Medical Group policies now explicitly prohibit ghostwriting, which is defined as the ‘practice of being named as an author on an article that contains substantial portions written by someone who is not listed as an author.’”

If you or a loved one has experienced serious side effects, birth defects or health complications with Paxil, contact Newsome Law Firm and fill out a case evaluation form today. Our team of attorneys has experience specific to complications associated with prescription medication. Not only can they give you the legal guidance you need, they can help you get the compensation you deserve.

References:

Feeley, Jef. (November 9, 2010) “Glaxo Failed to Warn About Paxil Risks, Lawyer Says at Philadelphia Trial.” Retrieved on December 14, 2010 from Bloomberg L.P.

Tillman, Traci. (December 3, 2010) “Med prof accused of ghostwriting.” Retrieved on December 14, 2010 from The Yale Daily News.

Drug Maker, GlaxoSmithKline, Pays $750 Million Over Alleged Violations

Drug Maker, GlaxoSmithKline, Pays $750 Million Over Alleged Violations

GlaxoSmithKline (GSK) reached a settlement with the U.S. Attorney’s Office over alleged manufacturing violations of government drug standards.  According to Business Wire, GSK will pay $750 million in fraud charges. $600 million will go to settle the civil case against the company while the remaining $150 million will pay a criminal fine. This case is groundbreaking because it is the first time a whistleblower lawsuit has been successfully filed, holding this drug manufacturer accountable for violating government standards.

Read more

Paxil birth defect lawsuits still mounting as GlaxoSmithKline shifts focus to other drugs

Paxil birth defect lawsuits still mounting as GlaxoSmithKline shifts focus to other drugs

Since 2005, the prescription anti-depression medicine Paxil and its parent company GlaxoSmithKline have been accused on a large scale of causing serious birth defects in children born to prescribed users of the drug. Hundreds of cases have been filed between 2005 and now, as women battling all forms of depression continued to use the drug while pregnant. Paxil was approved for prescription use by the Food and Drug Administration in 1999, and by 2005 the FDA had issued warnings that the drug may cause birth defects.

Read more
x
OVER $500,000,000 recovered
Newsome Melton has recovered over half a billion dollars for their clients.
Product Liability Lawyer - Newsome Melton

Please do not navigate away from this page until you receive a success notification.
Product Liability Lawyer - Newsome Melton